ºÚÁϳԹÏÍø

The Case Comprehensive Cancer Center (Case CCC) extends congratulations to Ruth Keri, PhD, professor of pharmacology and Case CCC Associate Director for Basic Research on her recent election to the Board of Directors for the Endocrine Society. Dr. Keri will serve a three-year term for the society w...

The Case Comprehensive Cancer Center extends congratulations to undergraduate Jack Kincaid on receiving first prize in the 2020 Michelson-Morley Research Competition in the Biological Sciences. Jack works in the lab of member Nathan Berger, MD, sponsored by the National Cancer Institute R25 Training...

A medical device based on technology developed by three faculty members from ºÚÁϳԹÏÍø and University Hospitals Cleveland Medical Center (UH) has won a prestigious 2020 Edison Best New Product Award. EsoCheck, a device designed to help detect precancerous changes in the es...

J. Alan Diehl has been appointed deputy director and chief operating officer of the Case Comprehensive Cancer Center, a collaboration of ºÚÁϳԹÏÍø, Cleveland Clinic and University Hospitals. This newly created role will provide substantive oversight of the cancer center to pur...

J. Alan Diehl has been appointed deputy director and chief operating officer of the Case Comprehensive Cancer Center, a collaboration of ºÚÁϳԹÏÍø, Cleveland Clinic and University Hospitals. This newly created role will provide substantive oversight of the cancer center to pur...

A study led by Nima Sharifi, MD (Hearn, Jama Oncol, 2020) found the adrenal-permissive HSD3B1 allele is associated with earlier castration resistance and shorter overall survival among men with low-volume metastatic prostate cancer. These findings lay the foundation for more personalized and effecti...

The following is a message from the Associate Director for Clinical Research, Mitchell Machtay, MD and Deputy Associate Director for Clinical Research, Mikkael Sekeres, MD. Patients with cancer often turn to clinical trials because their other treatment options are limited. Though there has been a ...

The Case Comprehensive Cancer Center has extended deadlines for a variety of open funding opportunities. Pilot project awards range from $10,000 to $180,000 and support innovative and impactful proposals that will generate key data for nationally competitive grants. View all open funding opportunit...

The Case Comprehensive Cancer Center’s Specialized Program of Research Excellence in Gastrointestinal Malignancies (GI SPORE) invites ºÚÁϳԹÏÍø faculty members to submit proposals to be considered for the Career Enhancement Program (CEP) Award and Developmental Research Project...

The Case Comprehensive Cancer Center (Case CCC) is pleased to announce that Lan Zhou, MD, PhD has accepted the role of Scientific Director of the Case Comprehensive Cancer Center (Case CCC) Hematopoietic Biorepository Cell Therapy Shared Resource. Dr. Zhou is an associate professor of pathology and ...